In the subset of patients with self-reported psoriatic arthritis, guselkumab demonstrated better maintenance of response and higher efficacy compared with secukinumab in the treatment of moderate to severe plaque psoriasis.
Investigators examined retrospective data of patients with juvenile idiopathic arthritis and other diseases who received live booster MMR or MMR + varicella while taking disease-modifying antirheumatic drugs, glucocorticosteroids or biological agents.
The ACP has issued a position paper that examines the professional duties and principles that should guide the response of colleagues and the profession to physician impairment.
Study evaluates the benefits of ocrelizumab on 48-week confirmed disability progression in MS observed in pooled OPERA I and OPERA II, as well as a 3 year ocrelizumab treatment in an open-label extension.
Study demonstrated efficacy in improving communication with the clinician, lowering the number of visits, and improving the coordination of single-day multi-service and therapeutic interventions in multiple sclerosis
The clinician workgroup achieved a consensus and report a 3-step iterative management algorithm for MS relapses.
The investigators of this Phase 3 study sought to evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release capsules to treat multiple sclerosis patients with walking impairment.
Investigators sought to determine the safety and efficacy of twice-daily dosing of arbaclofen ER in patients with spasticity due to multiple sclerosis.
Individuals with multiple sclerosis undergoing dimethyl fumarate therapy may be vulnerable to herpes simplex encephalitis.
Age- and sex-stratified comorbidity and concomitant medication use has been found among individuals with MS who have newly initiated disease-modifying drugs.
